+34 679 490 537info@nanbiosis.com

Posts Taged nanobiocell

1st Meeting with Cystic Fibrosis Patiens (NanoBioCel -ARNASA)

Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases”

The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and malnutrition

As there is no cure for the disease, daily treatment is the only option to have an acceptable quality of life

The NanoBioCell Research Group, which coordinates unit 10 of NANBIOSIS of the CIBER-BBN and the UPV/EHU, has a wide experience in comprehensive research into effective therapies for the treatment of cystic fibrosis and related diseases has organized the ‘First meeting with cystic fibrosis patients’ in the collaboration with ARNASA Bizkaia, (the Cystic Fibrosis Association of Bizkaia, made up of affected people, their families and volunteers who collaborate with the association)

Registration is free here. After registration you will receive a link to the online meeting

Read More

New Center for Research in Advanced Pharmaceutical Development

The NanoBioCel Research group, led by Jose Luis Pedraz, from CIBER-BBN and UPV/EHU, group that coordinates the Unit U10 Drug Formulation of NANBIOSIS -ICTS, together with the Provincial Council of Álava and the Center for Technological Research and Development TECNALIA, have launched last Thursday, January 21, the new Center for Research in Advanced Pharmaceutical Development, which will be located in the Lascaray Building, on the Álava campus of the UPV / EHU.

The objective of this center is to introduce new technologies in the pharmaceutical field and promote applied research in 3D Bio-printing, 3D Printing of medical devices and 3D Printing of new drugs.

This new center is a strategic and ambitious project, supported directly by the Provincial Council of Álava with a budget of € 2,500,000 that seeks to integrate the Álava region within the strategy proposed by the European Union in biosciences and technological development, sectors that have been boosted in the new investment initiative in response to the Coronavirus. This center is also a regional reference as a result of the leadership exercised by the NanoBioCel research group and a fruitful relationship of common projects to offer services to the pharmaceutical industry with Tecnalia2.

In the picture: Jose Luis Elejalde from Tecnalia, Javier Hernando from the Provincial Council of Alava, Pilar Garcia de Salazar, Lieutenant General Deputy and Provincial Deputy for Economic Development and Territorial Balance in the Provincial Council of Alava. Jose Luis Martin, Vice-Rector for Research of the UPV / EHU and Jose Luis Pedraz, IP NanoBioCel group.

Read More

NANBIOSIS Unit 10 of Drug Formulation participates in the European Project Position II

Nanobiocel, the CIBER-BNN – UPV-EHU group, led by José Luis Pedraz, Scientific Director of NANBIOSIS-ICTS U10 “Drug Formulation Unit” participates in the Position II European project, coordinated by Philips Electronics Nederland.

The project, funded through the Horizon 2020 call with a global budget of more than 50 million euros, will be developed during three years with the participation of 48 partners. Its general objective is to innovate in the production processes in the field of health to obtain state-of-the-art catheters. It will also include innovative treatments, such as cell therapy, which guide small capsules with cells with a regenerative effect to stimulate the recovery of damaged cardiac areas during the infarction.

The Nanobiocel group will be responsible for carrying out the formulation of the cells in hydrogels, for administration through the catheter at the cardiac level, for the regeneration of heart tissue.

In the development of the project, NANBIOSIS U10 “Drug Formulation Unit ” will participate. This Unit, located in the Faculty of Pharmacy of the UPV / EHU, has the capacity to design and evaluate classic dosage forms and new forms of biotechnological drugs, DNA, RNA and vaccines, using different methodologies based on micro and nanomedicine. This last methodology, based on the microencapsulation of cells, peptides, proteins and, in general, of biotechnological products, as well as the development and design of non-viral vectors for gene therapy, is one of the greatest singularities of this unit. It has the most advanced equipment for micro and nanoencapsulation.

The Eurpean project under Grant Agreement Ecsel-783132- POSOTION II 2017-IA, seeks to reverse the nowadays obsolete production of catheters (in the last decade there have been no innovations in this field). This justifies, from a business point, the investment in new R & D lines. In addition, it will introduce open technology platforms to increase miniaturization, the integration of electronics, wireless communications and their encapsulation. These technology platforms will renew catheter-based interventions, improving performance and reducing current production costs. It also seeks to break the current monopoly of US companies in the development and production of smart catheters.

Read More